Physician profile
Robin Bash
NPI 1730225210
$852.44
in general payments reported to CMS, 2019-2025
10 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Physical Medicine & Rehabilitation provider received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.80 · 2020: $80.34 · 2021: $76.25 · 2022: $14.20 · 2023: $194 · 2024: $230 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $651.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $324.33 | 2023-2025 | Haegarda, Andembry |
| Glaxosmithkline, LLC. | $120.98 | 2019-2025 | Nucala |
| Astrazeneca Pharmaceuticals Lp | $92.88 | 2021-2025 | Tezspire |
| Takeda Pharmaceuticals U.S.A., INC. | $88.69 | 2020-2022 | |
| Kaleo, INC. | $86.11 | 2023-2024 | Auvi-Q |
| Genentech USA, INC. | $48.57 | 2024 | Xolair |
| Phadia US INC. | $34.17 | 2023 | Immunocap |
| Genzyme Corporation | $26.78 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $16.42 | 2025 | Neffy |
| Merck Sharp & Dohme LLC | $13.51 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robin Bash listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.